Martine A. Rothblatt, United Therapeutics' chairperson and CEO, reported the sales in a Form 4 filing. This SEC report of insider stock trades was filed on November 12, 2026. The sales took place on November 11, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-11 |
| Date of Latest Transaction | 2026-11-11 |
| Buy/Sell | sell |
| Transaction Count | 14 |
| Shares Transacted | 9,500 |
| Price | $593.99 |
| Total Transaction Value | $5,642,869.59 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of UTHR shares, reported with transaction code S. The filing covers 14 sale transactions by Martine A. Rothblatt.
What was the average price of the transaction?
The average sale price was $593.99 per share across all 14 transactions. The available details give one average for the full group, without a separate price for each sale.
How did this transaction affect the insider's holdings?
The sales reduced the reported holdings by 9,500 shares, leaving 324,443 shares owned afterward. Those 9,500 shares made up 2.84% of the shares reported as held before the sales.
What's the total transaction value?
The total value of the 14 sales was $5,642,869.59 when rounded to cents. The value before rounding was $5,642,869.5895.
Are there any special circumstances around this transaction?
The available transaction information includes a reference to a Rule 10b5-1 plan, which sets trading instructions in advance. The filing's footnote text was not provided. That leaves it unclear whether the reference applies to all 14 sales or only some. The date the plan began, its terms, and its trading schedule are unknown.
For research purposes only; not investment advice.